Key Takeaways
- Revenue hit by price, not demand collapse: Q4 FY24 revenue fell 16.4% YoY driven by negative rate variance across product streams; full year down 6.8% with sluggish exports offset by domestic volume growth.
- Margins improved despite the top-line pressure: EBITDA margin expanded 130 bps YoY in Q4 and 140 bps for the full year, helped by stabilizing input costs and operational efficiencies.
- Export headwinds easing but not gone: Dollar shortages in South America and Africa have minimized, though management flagged geopolitical tensions in the Middle East as a watchpoint.
- FY25 is a volume-and-margin recovery story: Management targets 10% top-line growth despite an expected 5-8% negative rate variance, and aims to cross 14% EBITDA margin with a stretch goal of 15%.
- What to watch next quarter: Whether the Sayakha greenfield project commences on schedule by end-Q1 FY25, the pace of Baddi plant FDA clearance, and any early signal that export selling prices are stabilizing as guided.
Revenue & Volume Dynamics
- Price, not volume, drove the Q4 decline: Q4 FY24 revenue fell 16.4% YoY, majorly due to negative rate variance. Full-year revenue declined 6.8% on the same price pressure plus sluggish export demand for API and Specialty Chemicals.
- Domestic volumes held up on a tough base: Domestic market was almost flat with hardly 1% decline in Q4, which management considered good performance because the March '23 quarter had unusually high buying by formulation companies after prices collapsed in December '22, creating a high base.
- Export volumes were the real drag: Export market saw a degrowth of almost 15% in Q4, contributing to an overall negative 6% volume growth YoY. Heightened interest rates, dollar shortages, destocking, supply chain hurdles, and conservative ordering impacted export demand in select regions.
- Pricing has stopped falling: Prices declined through the December quarter, then stabilized from December to March and are not falling further. March '24 selling prices are expected to continue for FY25.
- The base-effect math for FY25: Because prices fell slowly each quarter in FY24, the first half of FY25 will see a little bit of negative price variation YoY, but the second half will see very minimal negative price variation because the base period already had lower prices.
- Composite selling price should rise: Export selling prices are expected to be stable, not necessarily increasing, but the composite selling price should go up due to an increase in the proportion of exports, which carry higher selling prices than domestic.
Adhish Patil: "As far as pricing environment of API is concerned, we saw decline in December quarter. Then from December to March quarter, the prices have almost stabilized now, so they are not falling further."
Margin Trajectory
- Gross margin improvement is structural: EBITDA margin improved 130 bps YoY in Q4 and 140 bps for the full year, driven by stabilization of input costs in the latter half of FY24 and operational efficiencies. Management projects further enhancement in gross margins, mostly driven by an upturn in selling price levels from anticipated export sales growth.
- Formulation margins got a permanent lift: Pinnacle's formulation margins increased due to a switch in business model from domestic CMO to value-added export business in Latin America, Asia, Africa, and regulated markets. Lower API prices had only a small positive impact. Management confirmed this margin level is not a one-off and will sustain.
- The FY25 margin ambition: Management is confident of crossing the 14% EBITDA margin mark and aims for 15% if the situation remains stable. The steady-state expectation at INR4,000 crores turnover is 15.5% to 16% EBITDA margin; 17-18% was acknowledged as slightly difficult to achieve.
- Operating leverage is a second-half story: Operating leverage is expected to kick in from H2 FY25 with improved capacity utilization, as the majority of the INR600 crores capex is completed and the balance releases cost alongside profit margin expansion and topline growth.
Adhish Patil: "So considering that negative rate variance, we would target to reach like 10% top line growth. We will target that in spite of negative rate variance. And as far as EBITDA is concerned, so we are now more and more confident that we should be crossing the 14% mark at the company level. And slowly, if the situation continues to be stable, then probably we'll try to reach the 15% mark."
Capacity & Capex
- The big capex cycle is nearly done: Majority of the INR600 crores capex is completed; the balance is expected to be completed soon. FY25 capex is budgeted at INR200-250 crores, and from FY26 onward it normalizes to INR150-200 crores, though some additional capex may be required for developing and registering more oncology products and one or two new API products.
- Sayakha greenfield on the near-term clock: The greenfield project at Gujarat Sayakha for specialty chemicals and intermediates is on track and planned to commence by the end of Q1 FY25, with scale-up in Q4 FY25.
- Tarapur dermatology project ramping: The greenfield project for dermatology products has commenced, with ramp-up planned throughout the first half of FY25.
- Oncology plant is commissioned and in the FDA queue: A brand-new oncology plant was commissioned a few quarters back; the first filing triggered a U.S. FDA inspection. The file has moved from the response renew department to the ORA inspection department, though the FDA calendar is packed from October to September and the file only moved to inspection from October onward.
- Capacity utilization stays in the late 70s by design: The company continuously adds small capacities via debottlenecking whenever demand is seen, so utilization does not spike higher.
- Top molecules face limited new competition: For the top 15 API molecules, apart from metformin, there has not been any significant capacity increase because these are mature molecules. The pressure was mainly due to inventory destocking. For trade molecules ranked 16th to 40th, capacity has been added, including by Aarti Drugs itself.
Adhish Patil: "apart from metformin product, there has not been any capacity increase because most of those top 15 molecules are mature molecules."
Oncology Pipeline
- A material revenue stream in the making: Management targets INR300-350 crores of additional revenue from 12 to 14 oral oncology products, taking 24 to 36 months considering approval times and product launches.
- Filings are front-loaded: Filings for the oncology molecules will happen over the next 6 to 18 months, with many day-one launches as patents expire from 2025 through 2027-28.
- The plant is already built and FDA-engaged: The oncology plant was commissioned a few quarters back, the first filing has triggered a U.S. FDA inspection, and the file is now with the ORA inspection department. Because there is a standing import alert on the API facility, the inspection would most likely be a supply zone inspection.
Regulatory & Plant Status
- Baddi formulation plant under FDA review: The U.S. FDA carried out an inspection at the Baddi plant operated by a subsidiary. None of the observations pertained to data integrity, and the company is working on resolving the reported observations. Management is optimistic of getting clearance at the earliest.
- FDA inspection timeline is uncertain: Status quo on the FDA front. A reminder has been sent to the FDA office. The file moved from the response renew department to the ORA inspection department, but the FDA calendar is packed from October to September, and the file was only moved to inspection from October onward.
- Dollar shortage issues have eased but geopolitics loom: Dollar shortage issues in South America and Africa are minimized compared to last year, but management noted the need to be watchful of current geopolitical tensions in the Middle East.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line growth | 10% growth despite ~5-8% negative rate variance | FY25 |
| EBITDA margin | Cross 14%; aim for 15% if situation remains stable | FY25 |
| Sayakha greenfield commencement | Project to commence operations | End of Q1 FY25 |
| Sayakha scale-up | Ramp to full scale | Q4 FY25 |
| Tarapur dermatology ramp-up | Ramp-up throughout H1 | H1 FY25 |
| Oncology revenue contribution | INR300-350 crores from 12-14 products | 24-36 months |
| Formulation revenue | Double from current ~INR300 crores | Next 3 years |
| Overall revenue target | INR4,000-4,500 crores | 5-6 years |
| Steady-state EBITDA margin | 15.5-16% at INR4,000 crores turnover | At scale |
| Volume growth target | ~15% volume growth | Coming years |
| FY25 capex | INR200-250 crores | FY25 |
| FY26 onward capex | INR150-200 crores (plus potential oncology/API capex) | FY26 onward |
| Baddi plant FDA clearance | Optimistic of getting clearance | At the earliest |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated revenue | ₹621 cr, decline of 16.4% YoY |
| Standalone revenue | ₹560.64 cr, decline of 19.6% YoY, of which 13.6% was negative rate variance |
| EBITDA | ₹87 cr, margin at 14.0%, improved 130 bps YoY |
| PAT | ₹47 cr, margin at 7.6% |
| Formulation segment revenue | ₹68 cr for the quarter; full year ₹325 cr, growth of 18.5% YoY |
| Standalone domestic revenue share | 67% of standalone revenue |
| Standalone export revenue share | 35% of standalone revenue |
| API volume growth (Q4 YoY) | -6% overall; domestic flat with -1%, export -15% |
| API volume growth (full year FY24) | 7% overall; domestic 16% to 17% |
| Net cash flow from operations | ₹359 cr as of March 31, 2024, versus ₹133 cr as of March 31, 2023 |
| Capex incurred (FY24) | ₹226 cr |
| Total debt (consolidated) | ₹563 cr; short-term ₹215 cr, long-term ₹348 cr |
| Debt-to-equity ratio | 0.44x consolidated, 0.4x standalone |
| Return on capital employed (FY24) | 14.2% |
| Return on equity (FY24) | 13.9% |
| Capacity utilization (excl. greenfield) | 75% to 79% |
| FY25 revenue growth target | 10% top line growth, despite ~5% to 8% negative rate variance |
| FY25 EBITDA margin target | crossing 14%, aiming for 15% if conditions remain stable |
| Oncology pipeline ANDAs filed (U.S.) | 1 filed so far, 12 to 14 molecules in pipeline over next 6 to 18 months |